Diffuse Alveolar Hemorrhage after Allogeneic Hematopoietic Stem-Cell Transplantation: Treatment with Recombinant Factor VIIa

Stephen M. Pastores, Esperanza Papadopoulos, Louis Voigt, Neil A. Halpern

Research output: Contribution to journalArticlepeer-review

74 Scopus citations

Abstract

Diffuse alveolar hemorrhage (DAH) is a serious pulmonary complication that occurs in patients undergoing hematopoietic stem-cell transplantation (HSCT). Current management strategies are limited to corticosteroids, platelet transfusions, and mechanical ventilator support to treat acute respiratory failure. Recombinant factor VIIa (rFVIIa) is an approved agent for the treatment of bleeding in patients with hemophilia A or B and the presence of inhibitors. We report a case of DAH after allogeneic HSCT that failed standard therapy and was then successfully treated with rFVIIa.

Original languageEnglish
Pages (from-to)2400-2403
Number of pages4
JournalChest
Volume124
Issue number6
DOIs
StatePublished - Dec 2003
Externally publishedYes

Keywords

  • Allogeneic hematopoietic stem-cell transplantation
  • Diffuse alveolar hemorrhage
  • Recombinant factor VIIa

Fingerprint

Dive into the research topics of 'Diffuse Alveolar Hemorrhage after Allogeneic Hematopoietic Stem-Cell Transplantation: Treatment with Recombinant Factor VIIa'. Together they form a unique fingerprint.

Cite this